Neurobehavioral Disorders
Novel Combination Therapy for Major Depressive Disorder Gets Priority Review
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Your search for major depressive disorder returned 6 results
Neurobehavioral Disorders
Negative Allosteric Modulator Gets Fast Track Status for Social Anxiety Disorder
The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial.
Neurobehavioral Disorders
Transcranial Magnetic Stimulation Device Cleared for Anxious Depression
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
Neurobehavioral Disorders
Prescription Digital Therapeutic for Anxiety, Depression Treatment Launched
Ensemble is an AI-powered digital mental health coach app designed to address the symptoms of MDD or GAD.
AAN 2015 Coverage
NBT System Gets FDA Clearance for Depression Treatment
The system is currently being assessed for its use in stroke rehabilition in the Phase 3 supplemental study 'E-FIT', involving 60 patients.
Neurobehavioral Disorders
Lithium Compared With Newer Therapies as Adjunct to Antidepressants
The likelihood of help or harm, also known as the risk/benefit ratio, was found to be more favorable for lithium.
- Loading...
Loading...
Next post in Neurobehavioral Disorders
Loading... 
Loading...